Does PF-1355 improve ventricular function and remodeling in mouse myocardial infarction models?
PF-1355, an oral myeloperoxidase inhibitor, protects against acute and chronic adverse effects of myocardial infarction in mice, suggesting potential for future translational studies.
PF-1355 is an oral myeloperoxidase (MPO) inhibitor that successfully decreased elevated MPO activity in mouse myocardial infarction models. Short duration PF-1355 treatment for 7 days decreased the number of inflammatory cells and attenuated left ventricular dilation. Cardiac function and remodeling improved when treatment was increased to 21 days. Better therapeutic effect was further achieved with early compared with delayed treatment initiation (1 h vs. 24 h after infarction). In conclusion, PF-1355 treatment protected a mouse heart from acute and chronic effects of MI, and this study paves the way for future translational studies investigating this class of drugs in cardiovascular diseases.
Ali et al. (Thu,) studied this question.